Skip to main content
Captor Therapeutics S.A. logo

Captor Therapeutics S.A. — Investor Relations & Filings

Ticker · CTX ISIN · PLCPTRT00014 LEI · 259400JHH1S2I2S4O735 WAR Professional, scientific and technical activities
Open in API
Filings indexed 920 across all filing types
Latest filing 2025-10-15 Regulatory Filings
Country PL Poland
Listing WAR CTX

About Captor Therapeutics S.A.

https://www.captortherapeutics.com/

Captor Therapeutics is a biopharmaceutical company focused on the discovery and development of novel therapeutics for diseases with high unmet medical needs. The company specializes in Targeted Protein Degradation (TPD), a technology that enables the elimination of disease-causing proteins previously considered "undruggable." Its core research and development activities are centered on creating new treatments for cancer and autoimmune diseases. To achieve this, Captor Therapeutics utilizes its proprietary Optigrade™ platform. This integrated drug discovery engine combines advanced technologies, including structural biology, proteomics, molecular modeling, and protein engineering, to identify and optimize novel drug candidates. The platform is designed to accelerate the development of degraders with superior therapeutic properties, aiming to provide new treatment options for severe conditions.

Recent filings

Filing Released Lang Actions
Zgłoszenie przez Akcjonariusza projektu uchwały w sprawie objętej porządkiem obrad NWZA - Content (PL)
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement (under 1,000 characters) from Captor Therapeutics S.A. regarding a shareholder proposal for an upcoming Extraordinary General Meeting (NWZ). It references a previous report and provides the text of a proposed resolution as an attachment. Since it is a brief notification regarding meeting materials rather than the full proxy statement or the meeting results themselves, it falls under the category of a general regulatory announcement.
2025-10-15 Polish
Zakończenie subskrypcji akcji serii W emitowanych w związku z realizacją programu motywacyjnego dla pracowników Spółki - Content (PL)
Share Issue/Capital Change Classification · 100% confidence The document details the completion of a private subscription for new shares (Series W) by Captor Therapeutics S.A. It provides specific data points regarding the number of shares issued, the subscription period, the number of participants, and the total value of the issuance. This is a formal announcement of a capital change resulting from a share issuance, which fits the definition of a Share Issue/Capital Change (SHA) filing.
2025-10-14 Polish
załącznik do raportu
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically a member of the management board (Tomáš Drmota) of Captor Therapeutics S.A. It explicitly references Article 19(1) of the Market Abuse Regulation (MAR). This type of disclosure, detailing the acquisition of shares by an insider, is classified as a Director's Dealing.
2025-09-30 Polish
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a notification regarding a transaction on company shares by a member of the Management Board (Tomáš Drmota). This falls under the category of insider trading or director's dealings, which is explicitly defined as 'Director's Dealing' (DIRS) in the provided taxonomy.
2025-09-30 Polish
Załącznik do raportu
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically a member of the Supervisory Board (Członek Rady Nadzorczej) of Captor Therapeutics S.A. It explicitly references Article 19(1) of the Market Abuse Regulation (MAR). This type of disclosure, detailing the acquisition of shares by an insider, is classified as a Director's Dealing.
2025-09-30 Polish
Informacja o transakcji na akcjach Spółki uzyskana w trybie art. 19 MAR - Content (PL)
Director's Dealing Classification · 100% confidence The document is a notification from a company (Captor Therapeutics S.A.) regarding a transaction on company shares by a member of the Supervisory Board (Paweł Holstinghausen Holsten). This is a classic disclosure of insider trading or director's dealing as required by regulatory frameworks like MAR (Market Abuse Regulation).
2025-09-30 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.